KRAS is the most frequently mutated oncogene in non-small cell lung cancer (NSCLC), and activating KRAS mutations predict poor outcome in response to conventional treatment regimens [1–3]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.